Updated
Inovio PharmaceuticalsINO · Healthcare
$1.22-15.86%
Market cap$100M
IndustryBiotechnology
Inovio Pharmaceuticals (INO) Revenue breakdown
By product, Revenue under collaborative research and development arrangements is the largest at 51% of fiscal 2021 revenue; Revenue under collaborative research and development arrangements from affiliated entities grew fastest, -29% a year over 5 years.
Revenue by product
Fiscal years, as Inovio Pharmaceuticals reports them in its 10-K filings; fiscal 2021 total $2M.
| Products | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | Share |
|---|---|---|---|---|---|---|---|
| Revenue under collaborative research and development arrangements | $6M | $28M | $30M | $4M | $5M | $902,260 | 51% |
| Other revenue | $27M | $10M | $171,588 | $237,536 | $786,904 | $627,188 | 35% |
| Revenue under collaborative research and development arrangements from affiliated entities | $1M | $765,828 | $449,524 | $235,649 | $1M | $245,310 | 14% |
| Other revenue from affiliated entities | — | $3M | — | $1,800 | — | — | — |
| Grants and miscellaneous revenue from affiliated entity | $340,563 | — | — | — | — | — | — |
Questions about Inovio Pharmaceuticals
Where does Inovio Pharmaceuticals make its money?
In fiscal 2021, by product: Revenue under collaborative research and development arrangements $902,260, Other revenue $627,188, Revenue under collaborative research and development arrangements from affiliated entities $245,310.
From Inovio Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.